Search hospitals
>
Connecticut
>
New Haven
Yale University School of Medicine
Claim this profile
New Haven, Connecticut 06510
Global Leader in Alzheimer's Disease
Global Leader in Type 1 Diabetes
Conducts research for Cancer
Conducts research for Obesity
Conducts research for Lung Cancer
728 reported clinical trials
61 medical researchers
Summary
Yale University School of Medicine is a medical facility located in New Haven, Connecticut. This center is recognized for care of Alzheimer's Disease, Type 1 Diabetes, Cancer, Obesity, Lung Cancer and other specialties. Yale University School of Medicine is involved with conducting 728 clinical trials across 782 conditions. There are 61 research doctors associated with this hospital, such as Patricia M Lorusso, Alessandro Santin, Amer M. Zeidan, and Charles Matouk.
Area of expertise
Alzheimer's Disease
Yale University School of Medicine has run 52 trials for Alzheimer's Disease. Some of their research focus areas include:
Type 1 Diabetes
Yale University School of Medicine has run 47 trials for Type 1 Diabetes. Some of their research focus areas include:
Top PIs
Patricia M Lorusso
Yale Cancer Center
7 years of reported clinical research
Alessandro Santin
Smilow Cancer Hospital at Yale New Haven
6 years of reported clinical research
Amer M. Zeidan
Yale Cancer Center
4 years of reported clinical research
Charles Matouk
Yale University
6 years of reported clinical research
Clinical Trials running at Yale University School of Medicine
Ovarian Cancer
Cancer
Colorectal Cancer
Multiple Myeloma
Lung Cancer
Gastrointestinal Stromal Tumor
Relapse
Chronic Lymphocytic Leukemia
Breast Cancer
Stroke
Heated Chemotherapy + Niraparib
for Ovarian Cancer
Patients will be registered prior to, during or at the completion of neoadjuvant chemotherapy given per standard institutional guidelines +/- bevacizumab on Day 1 every 21 days for 3-4 cycles. Registered patients who progress during neoadjuvant chemotherapy will not be eligible for iCRS and will be removed from the study. Following completion of neoadjuvant chemotherapy, interval cytoreductive surgery (iCRS) will be performed in the usual fashion in both arms. Patients will be randomized at the time of iCRS (iCRS must achieve no gross residual disease or no disease \>1.0 cm in largest diameter) to receive HIPEC or no HIPEC. Patients randomized to HIPEC Arm will receive a single dose of cisplatin (100mg/m2 IP over 90 minutes at 42 C) as HIPEC. After postoperative recovery patients will receive standard post-operative platinum-based combination chemotherapy. Patients randomized to surgery only (No HIPEC Arm) will receive postoperative standard chemotherapy after recovery from surgery. Both groups will receive an additional 2-3 cycles of platinum-based combination chemotherapy per standard institutional guidelines +/- bevacizumab for a maximum total of 6 cycles of chemotherapy (neoadjuvant plus post-operative cycles) followed by niraparib individualized dosing +/- bevacizumab until progression or 36 months (if no evidence of disease).
Recruiting
2 awards
Phase 3
Rina-S
for Ovarian Cancer
This phase 3 study will be conducted in different countries all over the world. The purpose of this study is to compare how well Rina-S works against platinum-resistant ovarian cancer compared to chemotherapy drugs that are already approved and used for platinum-resistant ovarian cancer. Treatment in this study could be Rina-S or it could be 1 of 4 indicated chemotherapy agents that are considered standard medical care. There is an equal (50:50) chance of getting Rina-S or an approved chemotherapy agent as treatment in this study. No one will know what treatment they are assigned to until the first dose. All participants will receive active drug; no one will be given placebo.
Recruiting
2 awards
Phase 3
4 criteria
LY3537982
for Cancer
This trial is testing a new drug called LY3537982 in cancer patients with the KRAS G12C mutation. It targets this mutation to stop cancer cells from growing. The study includes patients who haven't responded to other treatments or cannot tolerate them. LY3537982 is a new drug targeting the KRAS G12C mutation, similar to previously approved drugs like sotorasib and adagrasib.
Recruiting
1 award
Phase 1 & 2
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Yale University School of Medicine?
Yale University School of Medicine is a medical facility located in New Haven, Connecticut. This center is recognized for care of Alzheimer's Disease, Type 1 Diabetes, Cancer, Obesity, Lung Cancer and other specialties. Yale University School of Medicine is involved with conducting 728 clinical trials across 782 conditions. There are 61 research doctors associated with this hospital, such as Patricia M Lorusso, Alessandro Santin, Amer M. Zeidan, and Charles Matouk.
Where is Yale University School of Medicine located?
To reach Yale University School of Medicine hospital in New Haven, Connecticut, exit I-95 at Exit 47 and follow the Route 34 connector. Enter the Air Rights Garage and proceed to the 4th floor to access the hospital via a bridge. Alternatively, use GPS with the destination address 35 Park Street, New Haven, CT 06519.
Who should I call to ask about financial aid or insurance network?
**Yale University School of Medicine Hospital Financial Assistance:** - **Office of Financial Aid:** Located at Harkness Building D, ESH 202, 367 Cedar Street, New Haven, CT 06510 USA. For appointments or inquiries, email is available. - **Billing and Finance:** For insurance-related questions, bill inquiries, coordination of benefits, and premium payments, contact Yale Health's Billing and Finance Department at 866-341-0673. Credit card payments can be made by calling 203-436-8882 or through the online pay portal. - **Patient Advocacy:** For assistance with issues or complaints, reach out to the Patient Advocacy Department at 1-203-785-2140 or via email at YMPatientAdvocacy@yale.edu. - **Central Billing Line:** For questions about your bill, call Yale Medicine's Central Billing Line at 1-800-826-9922.
What insurance does Yale University School of Medicine accept?
The Yale University School of Medicine, part of the Yale New Haven Health System, accepts most major managed care and governmental health insurance plans in the Northeast. Patients are advised to directly verify coverage, benefit levels, and any referral or authorization requirements with their health insurance plan. Yale University faculty and staff have access to various medical, dental, and vision plan options, including Yale Health, Aetna medical plans, and Delta Dental, and should review the eligibility requirements and coverage guidelines to select the best plan.
What awards or recognition has Yale University School of Medicine received?
Yale University School of Medicine, along with Yale New Haven Hospital, is renowned for significant contributions to biomedical research and healthcare advancements. They engage in a pioneering collaboration with University College London to enhance global health through translational medicine. Yale School of Medicine is distinguished by its extensive clinical research, including hundreds of annual trials aimed at evaluating new medical treatments' safety and effectiveness.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.